Leash Biosciences has proprietary small molecule hits for >500 human targets, including transcription factors, ubiquitin modifiers, cytokines, and more, all discovered in our high-throughput protein production and screening laboratory.

The sheer size and diversity of our data - thousands of screens totaling ~35B physical measurements - has also enabled state-of-the-art AI performance.

We're actively seeking partners who share our vision in pushing ML beyond structure prediction. We're interested in fundraising as well as partnering our data/capabilities, and a few early stage programs.